

TABLE 1. Influenza vaccines — United States, 2016–17 influenza season\*

Trade name	Manufacturer	Presentation	Age indication	Mercury (from thimerosal), µg/0.5mL	Latex	Route
<b>Inactivated Influenza Vaccine, quadrivalent (IIV4), standard dose<sup>†</sup></b>						
Fluarix Quadrivalent	GlaxoSmithKline	0.5 mL single-dose prefilled syringe	≥3 yrs	NR	No	IM <sup>§</sup>
Flulaval Quadrivalent	ID Biomedical Corp. of Quebec (distributed by GlaxoSmithKline)	0.5 mL single-dose prefilled syringe	≥3 yrs	NR	No	IM
		5.0 mL multi-dose vial	≥3 yrs	<25	No	IM
Fluzone Quadrivalent	Sanofi Pasteur	0.25 mL single-dose prefilled syringe	6 through 35 mos	NR	No	IM
		0.5 mL single-dose prefilled syringe	≥36 mos	NR	No	IM
		0.5 mL single-dose vial	≥36 mos	NR	No	IM
		5.0 mL multi-dose vial	≥6 mos	25	No	IM
Fluzone Intradermal Quadrivalent <sup>¶</sup>	Sanofi Pasteur	0.1 mL single-dose prefilled microinjection system	18 through 64 yrs	NR	No	ID**
<b>Inactivated Influenza Vaccine, quadrivalent, cell culture-based (ccIIV4), standard dose<sup>†</sup></b>						
Flucelvax Quadrivalent	Seqirus	0.5 mL single-dose prefilled syringe	≥4 yrs	NR	No	IM
<b>Inactivated Influenza Vaccine, trivalent (IIV3), standard dose<sup>†</sup></b>						
Afluria	Seqirus	0.5 mL single-dose prefilled syringe	≥9 yrs <sup>††</sup>	NR	No	IM
		5.0 mL multi-dose vial	≥9 yrs <sup>††</sup> (needle and syringe) 18 through 64 years (jet injector)	24.5	No	IM
Fluvirin	Seqirus	0.5 mL single-dose prefilled syringe	≥4 yrs	≤1	Yes <sup>§§</sup>	IM
		5.0 mL multi-dose vial	≥4 yrs	25	No	IM
<b>Adjuvanted Inactivated Influenza Vaccine, trivalent (aIIV3), standard dose<sup>†</sup></b>						
Fluad	Seqirus	0.5 mL single-dose prefilled syringe	≥65 yrs	NR	Yes <sup>§§</sup>	IM
<b>Inactivated Influenza Vaccine, trivalent (IIV3), High Dose<sup>¶¶</sup></b>						
Fluzone High-Dose	Sanofi Pasteur	0.5 mL single-dose prefilled syringe	≥65 yrs	NR	No	IM
<b>Recombinant Influenza Vaccine, trivalent (RIV3)<sup>***</sup></b>						
Flublok	Protein Sciences	0.5 mL single-dose vial	≥18 yrs	NR	No	IM
<b>Live Attenuated Influenza Vaccine, quadrivalent (LAIV4)<sup>†††</sup></b>						
FluMist Quadrivalent	MedImmune	0.2 mL single-dose prefilled intranasal sprayer	2 through 49 yrs	NR	No	NAS

**Abbreviations:** ACIP = Advisory Committee on Immunization Practices; ID = intradermal; IM = intramuscular; NAS = intranasal; NR = not relevant (does not contain thimerosal).

\* Immunization providers should check Food and Drug Administration–approved prescribing information for 2016–17 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm>. Availability of specific products and presentations might change and differ from what is described in this table.

<sup>†</sup> Standard dose intramuscular IIVs contain 15 µg of each vaccine HA antigen (45 µg total for trivalents and 60 µg total for quadrivalents) per 0.5mL dose.

<sup>§</sup> For adults and older children, the recommended site for intramuscular influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration may be found in the ACIP General Recommendations on Immunization, available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm>.

<sup>¶</sup> Quadrivalent inactivated influenza vaccine, intradermal: a 0.1-mL dose contains 9 µg of each vaccine HA antigen (36 µg total).

\*\* The preferred injection site is over the deltoid muscle. Fluzone Intradermal Quadrivalent is administered using the delivery system included with the vaccine.

<sup>††</sup> Age indication per package insert is ≥5 years; however, ACIP recommends that Afluria not be used in children aged 6 months through 8 years because of increased risk for febrile reactions noted in this age group with Seqirus' 2010 Southern Hemisphere IIV3. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5 through 8 years who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine. Afluria may be used in persons aged ≥9 years. Afluria is licensed for administration by jet injector for persons aged 18 through 64 years only.

<sup>§§</sup> Syringe tip cap might contain natural rubber latex.

<sup>¶¶</sup> High-dose IIV3 contains 60 µg of each vaccine antigen (180 µg total) per 0.5mL dose.

<sup>\*\*\*</sup> RIV3 contains 45 µg of each vaccine HA antigen (135 µg total) per 0.5mL dose.

<sup>†††</sup> ACIP recommends that Flumist (LAIV4) not be used during the 2016–17 season.